The major, Switzerland-based, global pharmaceutical company Novartis has just agreed to acquire Endocyte — the developer of both Lu-177- PSMA-617 and Ac-225-PSMA-617, which are in clinical trials for the treatment of advanced forms of prostate cancer. 115 more words
Tags » Novartis
Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO
Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursday, cancer drug maker Allogene Therapeutics pulled off the biggest public offering… 319 more words
Perrigo looks for stability in its third CEO since March.
Perrigo, the leading maker of private-label over-the-counter drugs, is once again testing investors patience with a surprise management change. But that unsettling news also creates a future opportunity. 198 more words
Breakthrough leukemia treatment backfires in 'exceptionally rare' case
A highly unusual death has exposed a weak spot in a groundbreaking cancer treatment: One rogue cell, genetically altered by the therapy, can spiral out of control in a patient and cause a fatal relapse. 807 more words
An Extensive Report On DNA Vaccines Market 2018 Global Analysis By Key Players – Sanofi Aventis, Pfizer, Novartis, Merck, GlaxoSmithKline, ABL, Immunologicals, Xenetic Biosciences, QED Biosciences
DNA Vaccines Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. 864 more words
Once Daily: September 26, 2018
Today’s Essential Reading:
FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases ( 73 more words
Jordin Sparks teams up with Novartis and SCDAA
From press release:
Novartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project… 970 more words
